mAb Quality Control and
Analytical Development
Specialized mAb characterization, method development, and QC strategy
from early potency assay design through transfer-ready analytical packages
and BLA-stage comparability analytics.
MAB ANALYTICAL DEVELOPMENT
Building Analytical Programs That
Support Development, Release, and Lifecycle
DES Pharma supports analytical development and quality control programs for monoclonal antibodies across early development, clinical manufacturing, and commercial readiness. Our teams help sponsors design analytical strategies that reflect the complexity of mAb products, including higher-order structure, charge heterogeneity, glycosylation, aggregation, fragmentation, potency, and stability. We build method packages that support both product understanding and phase-appropriate control.
Our analytical support spans physicochemical, structural, and functional characterization. That includes potency assay planning, charge variant profiling, glycan analysis, peptide mapping, intact and subunit mass analysis, aggregation assessment, and stability-indicating method development. We help teams select the right methods for the stage of development, define what must be measured as a critical quality attribute, and connect analytical work to process development, release testing, comparability, and regulatory submissions.
As programs mature, we support transfer-ready analytical packages for QC use, method qualification and validation planning, reference standard strategy, and comparability analytics for manufacturing or site changes. The goal is to build an mAb analytical program that is technically sound, clinically relevant, and practical to maintain across the product lifecycle.
mAb Characterization ScopePhysicochemical, Structural
and Functional Methods
Functional and Potency
Cell-Based Potency
Binding / ELISA
FcRn / ADCC / CDC
Structural and Identity
Peptide Mapping
Intact Mass
Subunit Analysis
HOS Assessment
Purity and Variants
icIEF
CEX-HPLC
SEC / SEC-MALS
Glycan Profiling
DLS / MFI
Stability and Degradation
Stability-Indicating Methods
Forced Degradation
Aggregation Monitoring
CQA and METHOD STRATEGY
Critical Quality Attributes and
Recommended Control Methods
A useful mAb analytical strategy combines orthogonal methods to assess identity, purity, potency, structure, and stability.
Each method should answer a specific quality question and support decisions
across development, release, and lifecycle management.
Potency
Recommended Methods
Fit-for-purpose functional methods aligned with the product mechanism of action. Required for release, comparability, and ICH Q6B specifications. Method platform selected based on MOA, development stage, and QC transfer considerations.
Charge Variants
Recommended Methods
Acidic and basic species profiling for charge heterogeneity trend assessment across process changes, stability timepoints, and comparability studies. Orthogonal platforms increase confidence for BLA-stage control.
Glycosylation
Recommended Methods
Sialylation and fucosylation assessment linked to product consistency and Fc effector function. Critical for mAbs where glycan profile impacts ADCC activity, PK, or immunogenicity risk assessment.
Aggregation & Particles
Recommended Methods
Orthogonal coverage of soluble aggregates through sub-visible and visible particles. SEC as primary release method; SEC-MALS, DLS, and MFI for characterization, stability, and comparability packages per ICH Q6B and FDA particle guidance.
Identity & Sequence Confirmation
Recommended Methods
Sequence confirmation, disulfide mapping, and higher-order identity as required by ICH Q6B. Peptide mapping is anchor characterization; intact and subunit mass support comparability and lot release identity confirmation.
Product-Related Variants
Recommended Methods
Monitoring of deamidation, oxidation, clipping, and sequence variants across stability and process development. Structural variants with potential functional impact require risk-based assessment and inclusion in comparability analytical panels.
Fc Effector Function
Recommended Methods
Applied where FcRn-mediated half-life, ADCC, CDC, or related Fc activity is relevant to the molecule's mechanism or safety profile. Assessment of glycosylation impact on Fc function is often paired with glycan profiling data.
Stability-Indicating Methods
Recommended Methods
Forced degradation study design to identify degradation pathways and confirm method sensitivity per ICH Q5C and Q2(R1). Stability-indicating methods anchor the formal stability program, shelf-life submission, and formulation comparisons.
FunctionalPotency
+
Potency
Recommended Methods
Fit-for-purpose functional methods aligned with the product mechanism of action. Required for release, comparability, and ICH Q6B specifications. Method platform selected based on MOA, development stage, and QC transfer considerations.
StructuralCharge Variants
+
Charge Variants
Recommended Methods
Acidic and basic species profiling for charge heterogeneity trend assessment across process changes, stability timepoints, and comparability studies. Orthogonal platforms increase confidence for BLA-stage control.
StructuralGlycosylation
+
Glycosylation
Recommended Methods
Sialylation and fucosylation assessment linked to product consistency and Fc effector function. Critical for mAbs where glycan profile impacts ADCC activity, PK, or immunogenicity risk assessment.
PurityAggregation & Particles
+
Aggregation & Particles
Recommended Methods
Orthogonal coverage of soluble aggregates through sub-visible and visible particles. SEC as primary release method; SEC-MALS, DLS, and MFI for characterization, stability, and comparability packages per ICH Q6B and FDA particle guidance.
IdentityIdentity & Sequence Confirmation
+
Identity & Sequence Confirmation
Recommended Methods
Sequence confirmation, disulfide mapping, and higher-order identity as required by ICH Q6B. Peptide mapping is anchor characterization; intact and subunit mass support comparability and lot release identity confirmation.
PurityProduct-Related Variants
+
Product-Related Variants
Recommended Methods
Monitoring of deamidation, oxidation, clipping, and sequence variants across stability and process development. Structural variants with potential functional impact require risk-based assessment and inclusion in comparability analytical panels.
FunctionalFc Effector Function
+
Fc Effector Function
Recommended Methods
Applied where FcRn-mediated half-life, ADCC, CDC, or related Fc activity is relevant to the molecule's mechanism or safety profile. Assessment of glycosylation impact on Fc function is often paired with glycan profiling data.
StabilityStability-Indicating Methods
+
Stability-Indicating Methods
Recommended Methods
Forced degradation study design to identify degradation pathways and confirm method sensitivity per ICH Q5C and Q2(R1). Stability-indicating methods anchor the formal stability program, shelf-life submission, and formulation comparisons.
PHASE-APPROPRIATE SERVICESAnalytical Development and
Quality City Services for mAb Programs
Our analytical consulting is organized around two interconnected workstreams, the development program that generates product knowledge, and the QC infrastructure that controls it.
Method Design, Characterization and Development-Stage Analytics
Building the analytical foundation from first molecule characterization through transfer-ready method packages.
- Potency assay development aligned with product mechanism and phase of development
- Glycan analysis strategy for product quality and Fc-related function assessment
- Aggregation and particle analysis using SEC, SEC-MALS, DLS, and related orthogonal tools
- Stability-indicating method development for drug substance and drug product
-
Charge variant characterization using CEX-HPLC
and icIEF - Structural characterization using intact mass, subunit analysis, and peptide mapping
- Method selection and phase-appropriate qualification planning for key critical quality attributes
- Reference standard and control sample strategy for development and transfer
- Cell-based potency assay design and troubleshooting
- Glycan mapping and Fc-related characterization strategy
- Forced degradation design and interpretation for stability programs
- Binding assay and ELISA development for product-specific activity assessment
- Intact mass and peptide mapping support for product identity and variant analysis
- Analytical comparability planning after process or site changes
Release Testing, Method Transfer and QC Lifecycle Support
From release panel design through qualification, trending, and inspection-ready documentation.
- Release panel design for identity, purity, potency, and product-related variants
- Qualification and validation planning for commercial-facing analytical methods
- Trending and lifecycle management for critical analytical attributes
- Comparability analytical packages for process, site, or scale changes
- QC method transfer planning for internal labs, CDMOs, and contract testing partners
- Specification justification linked to process knowledge and product characterization
- OOS, OOT, and deviation support for mAb analytical investigations
- Data integrity and documentation structures suited to inspection and submission review
MAB ANALYTICAL EXPERTISE
Analytical Strategy
That
Connects
Development to Quality Control
A strong mAb analytical package does more than describe the molecule at one point in time. It supports decisions across process development, release, stability, and comparability. DES Pharma helps sponsors build analytical programs that connect early characterization with later QC use, so methods chosen in development remain practical for qualification, transfer, and ongoing lifecycle support.
- Potency strategy linked to biological relevance and control expectations
- Orthogonal characterization of charge, glycan, aggregate, and structural attributes
- Release and stability methods selected for long-term QC suitability
- Comparability analytics for manufacturing and process evolution
- Documentation support for IND, BLA, and lifecycle submissions
Potency and Bioassay Strategy
Cell-based, binding, and functional assay design. Platform selection for QC transfer suitability, comparability sensitivity, and regulatory acceptance calibrated to product MOA and phase expectations.
Charge and Glycan Characterization
icIEF and CEX-HPLC for charge heterogeneity, N-glycan profiling for fucosylation, sialylation, and high-mannose assessment. Orthogonal strategy for comparability and release control.
Aggregation and Particle Analysis
SEC for routine release, SEC-MALS for absolute molecular weight determination, DLS for hydrodynamic sizing, and micro-flow imaging (MFI) or nanoparticle tracking analysis (NTA) for sub-visible particle characterization in development and comparability studies.
Comparability and QC Transfer
Analytical comparability package design per ICH Q5E, selecting the right methods, defining acceptance criteria, and building documentation structures that support regulatory review and lifecycle submissions.
Why DES Pharma
What We Bring to Your
mAb Analytical Program
Practical analytical chemistry and regulatory consulting applied with phase-appropriate rigor across your development lifecycle, bridging early physicochemical characterization with inspection-ready commercial Quality Control systems.
Method Selection Expertise
We know which methods work well in development and which translate into QC environments. Our recommendations balance scientific rigor with the practical constraints of qualification, transfer, and long-term use.
Development-to-QC Continuity
We build analytical programs with lifecycle in mind, ensuring characterization work informs release panel design, specification setting, and the comparability strategies that arise as programs evolve.
Regulatory-Ready Documentation
Method development reports, validation plans, and comparability analytical packages are structured for direct use in IND filings, BLA Module 3, and agency meeting packages, not for rewriting later.
Potency Assay Specialization
Potency is the most complex and highest-risk element of most mAb analytical programs. We bring specific expertise in assay design, qualification, transfer, and troubleshooting across cell-based and binding platforms.
Comparability Analytics
When processes change, analytical comparability packages need the right breadth, sensitivity, and structure. We design panels that satisfy ICH Q5E requirements and hold up to regulatory scrutiny.
CDMO and CRO Interface
We help sponsors manage analytical work across CDMOs and contract testing laboratories, from method transfer protocols and qualification acceptance criteria to oversight during execution and report review.
REGULATORY FRAMEWORK Standards and Guidance That Shape mAb Analytical Strategy
mAb analytical programs are evaluated against an interconnected set of ICH guidelines, FDA guidance documents, and compendial standards. We help sponsors understand how these apply at each stage and build programs that satisfy expectations without unnecessary complexity.
Analytical Lifecycle Milestones
Pre-IND
Characterization panel, potency platform selection, initial stability methods
Phase 1 and Phase 2
Extended ICH Q6B characterization, release panel definition, reference standard strategy
Phase 3 Pivotal
Method qualification/validation, specification setting, comparability analytics
BLA Submission and Post-Approval
Validation packages, transfer documentation, lifecycle trending, variation analytics
REGULATORY REFERENCE FRAMEWORK
ICH Q6B
ICH Q2(R1/R2)
ICH Q5C
ICH Q5E
ICH Q14
FDA Guidance
Get Started
Build an mAb Analytical
Program That Lasts
Whether you need a phase-appropriate characterization strategy or a BLA-ready analytical package, our consultants can define the right approach for your program and stage.